Table 6. Reported reasons for changing initial HAART regimen in First Year.
| FH-Argentina | HUCFF-Brazil | FA-Chile | GHESKIO-Haiti | IHSS/HE-Honduras | INNSZ-Mexico | IMTAvH-Peru | Combined | |
| (n = 720) | (n = 522) | (n = 546) | (n = 1646) | (n = 324) | (n = 414) | (n = 854) | (n = 5026) | |
| Changed Regimens | ||||||||
| (% of HAART initiators) | 223 (31.0%) | 151 (28.9%) | 154 (28.2%) | 324 (19.7%) | 52 (16.0%) | 77 (18.6%) | 307 (35.9%) | 1288 (25.6%) |
| Reasons for Changing | ||||||||
| (% of HAART initiators) | ||||||||
| Adverse Events | 119 (16.5%) | 79 (15.1%) | 111 (20.3%) | 133 (8.1%) | 39 (12%) | 40 (9.7%) | 199 (23.3%) | 720 (14.3%) |
| Types of Adverse Events a | ||||||||
| Hematology b | 31 (4.3%) | 25 (4.8%) | 41 (7.5%) | 70 (4.3%) | 12 (3.7%) | 22 (5.3%) | 134 (15.7%) | 335 (6.7%) |
| Skin | 29 (4%) | 9 (1.7%) | 40 (7.3%) | 20 (1.2%) | 5 (1.5%) | 0 (0%) | 47 (5.5%) | 150 (3%) |
| Intolerance | 46 (6.4%) | 18 (3.4%) | 9 (1.6%) | 7 (0.4%) | 7 (2.2%) | 5 (1.2%) | 3 (0.4%) | 95 (1.9%) |
| Nervous System, Central | 6 (0.8%) | 10 (1.9%) | 10 (1.8%) | 23 (1.4%) | 10 (3.1%) | 1 (0.2%) | 8 (0.9%) | 68 (1.4%) |
| Gynecomastia/Abnormal Fat Dist. | 1 (0.1%) | 1 (0.2%) | 0 (0%) | 16 (1%) | 0 (0%) | 0 (0%) | 2 (0.2%) | 20 (0.4%) |
| Liver | 2 (0.3%) | 4 (0.8%) | 2 (0.4%) | 0 (0%) | 0 (0%) | 0 (0%) | 9 (1.1%) | 17 (0.3%) |
| Nervous System, Peripheral | 3 (0.4%) | 2 (0.4%) | 6 (1.1%) | 2 (0.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 13 (0.3%) |
| Kidney | 0 (0%) | 2 (0.4%) | 0 (0%) | 0 (0%) | 0 (0%) | 8 (1.9%) | 0 (0%) | 10 (0.2%) |
| Other Adverse Events c | 2 (0.3%) | 7 (1.3%) | 3 (0.5%) | 0 (0%) | 1 (0.3%) | 3 (0.7%) | 1 (0.1%) | 17 (0.3%) |
| Not Specified | 2 (0.3%) | 5 (1%) | 1 (0.2%) | 2 (0.1%) | 7 (2.2%) | 1 (0.2%) | 0 (0%) | 18 (0.4%) |
| Failure | 5 (0.7%) | 12 (2.3%) | 2 (0.4%) | 7 (0.4%) | 0 (0%) | 16 (3.9%) | 22 (2.6%) | 64 (1.3%) |
| Better Regimen Available/ | ||||||||
| Simplification | 5 (0.7%) | 0 (0%) | 13 (2.4%) | 48 (2.9%) | 1 (0.3%) | 9 (2.2%) | 0 (0%) | 76 (1.5%) |
| Drug Supply Problems | 2 (0.3%) | 3 (0.6%) | 0 (0%) | 73 (4.4%) | 1 (0.3%) | 0 (0%) | 10 (1.2%) | 89 (1.8%) |
| Abandonment/Adherence Failure | 11 (1.5%) | 0 (0%) | 16 (2.9%) | 3 (0.2%) | 3 (0.9%) | 2 (0.5%) | 19 (2.2%) | 54 (1.1%) |
| Pregnancy-Related | 5 (0.7%) | 0 (0%) | 0 (0%) | 21 (1.3%) | 1 (0.3%) | 0 (0%) | 0 (0%) | 27 (0.5%) |
| Tuberculosis-Related | 1 (0.1%) | 2 (0.4%) | 1 (0.2%) | 23 (1.4%) | 0 (0%) | 2 (0.5%) | 12 (1.4%) | 41 (0.8%) |
| Other Reasons for Changing | 20 (2.8%) | 5 (1%) | 10 (1.8%) | 15 (0.9%) | 3 (0.9%) | 1 (0.2%) | 27 (3.2%) | 81 (1.6%) |
| Unknown | 55 (7.6%) | 50 (9.6%) | 1 (0.2%) | 1 (0.1%) | 4 (1.2%) | 7 (1.7%) | 18 (2.1%) | 136 (2.7%) |
a
Does not necessarily add to total number of adverse events because some patients experienced multiple events which prompted regimen change.
b
Among those with a hematological adverse event, 73.4% were associated with anemia, 3.9% were not associated with anemia, and information regarding anemia was unspecified for the remaining 22.7%.
c
Includes lactic acidosis (5), hypersensitivity reaction (2), and metabolic/dislipidemia (1).